RH IFN-G (AF)
Referentie 100-77AF-20UG
Formaat : 20UG
Merk : FUJIFILM
Recombinant Human IFN-γ
Interferon gamma (IFN-γ) is a type II interferon that is critical during adaptive and innate immune responses to infection. IFN-γ is produced by T cells and natural killer cells following antigen-specific activation. IFN-γ binds IFN-γ receptors (IFN-γ R1 and IFN-γ R2), which are expressed on most immune cells, to activate the JAK-STAT pathway. IFN-γ-induced signaling increases the expression of class 1 major histocompatibility complex (MHC) molecules. Human IFN-γ is not cross-reactive with mouse IFN-γ.
Product images on the website are not representative of actual product, including, but not limited to differences in cap color, tube type, or label format.
Viral Challenge Assay
Figure 1. Recombinant Human IFNgamma activity measured in viral challenge assay using EMC virus on A549 cells.
Instructions
Centrifuge vial before opening. Suspend the product by gently pipetting the above recommended solution down the sides of the vial. DO NOT VORTEX. Allow several minutes for complete reconstitution. If a precipitate is observed, centrifuge the solution thoroughly and use only the soluble fraction (removing it from the precipitate). A 10% overfill has been added to compensate for any loss of protein in the precipitate. For prolonged storage, dilute to working aliquots in a 0.1% BSA solution, store at -80°C and avoid repeat freeze thaws.
Technical Specifications
| Alternate Names | Type II interferon, T cell interferon, Immune Interferon, MAF |
| Accession Number | P01579 |
| Source | Genetically modified E.coli |
| Predicted Molecular Mass | Monomer, 16.9 kDa (144 aa) |
| AA Sequence | MQDPYVKEAE NLKKYFNAGH SDVADNGTLF LGILKNWKEE SDRKIMQSQI VSFYFKLFKN FKDDQSIQKS VETIKEDMNV KFFNSNKKKR DDFEKLTNYS VTDLNVQRKA IHELIQVMAE LSPAAKTGKR KRSQMLFQGR RASQ |
| Formulation | Lyophilized from a 0.2 µm filtered solution containing 20 mM sodium phosphate, 2% trehalose, 4% mannitol, and 0.1% Tween80, pH 6.5 |
| Product Reconstitution | Sterile water at 0.1 mg/mL |
| Country of Origin | USA |
| Specification* | Method of Determination | Acceptance Criteria |
| Purity | Reducing and Non-Reducing SDS PAGE | ≥ 95% |
| Endotoxin | Kinetic LAL | ≤ 0.1 EU/µg |
| Biological Activity (ED50) | Ability to induce cytotoxicity of HT-29 cells by rh IFN-γ | ≤ 0.3 ng/mL; ≥ 3.3 x 106 units/mg |
*Lot-specific values for the above specifications are supplied with each product on its corresponding COA. The values provided here are minimum expected values to pass internal requirements.